Obagi Medical Products Releases Results of a Clinical Trial Showing Optimized Patient Outcomes When Condition & Enhance System is Used in Combination with Botulinum Toxin Type A
Clinical study reveals patients using Condition & Enhance™ in conjunction with BOTOX® treatments achieved an 86 percent overall improvement in facial appearance vs. 8 percent who used a standard skincare regimen with BOTOX®
BOSTON--(BUSINESS WIRE)--Jul 30, 2009 - Obagi Medical Products, Inc. (Nasdaq: OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced positive study results at the American Academy of Dermatology's (AAD) Summer Academy Meeting in Boston, Mass., showing that the use of its Condition & Enhance System, when combined with Botulinum Toxin Type A treatments (BOTOX®), provides greater improvement in overall facial appearance, as well as increased patient satisfaction, vs. BOTOX treatments with placebo.
“I regularly have patients come in and ask for BOTOX or other aesthetic procedures, but they have aged skin that doesn't always look markedly improved with injectables alone. This data clearly highlights the fact that by adding Condition & Enhance to an injectable patients' treatment regimen, you are addressing all facets of aging skin for optimal results which ultimately improves patient outcome and satisfaction, even in patients who have previously had BOTOX,” said Joel Schlessinger, MD, board certified dermatologist from Omaha, Neb., director of Skin Specialists P.C., and lead investigator of the study. “And perhaps even more importantly, 100% of study participants using the Condition & Enhance System wished to continue treatment after the close of the study.”
At the conclusion of the study, physician ratings of overall improvement in facial appearance were significantly greater with the Condition & Enhance System + BOTOX as compared to BOTOX with a standard skincare regimen. Also, it was found that 86 percent of Condition & Enhance + BOTOX patients achieved an overall improvement in facial appearance vs. 8 percent using BOTOX with a standard skincare regimen by the end of the trial. In addition, statistically significant benefits were seen in evenness of facial skin color tone and facial skin texture, as well as improved levels of skin laxity and fine lines and wrinkles.
Similarly, the Condition & Enhance System was clinically proven to increase patient satisfaction: 82 percent of study participants had peers notice a positive change in overall facial appearance, as compared to 16 percent of study participants in the standard skincare group. Study participants also reported the following by the conclusion of the trial (120 days):
“At Obagi Medical Products, we strive to provide physicians and their patients with the most effective skincare treatments available,” said Steve Carlson, President & CEO, Obagi Medical Products, Inc. “We are very pleased with the results of this particular study. They further validate the results of previous studies showing the significant benefit of using Condition & Enhance in complement with non-surgical procedures.”
Participants in the multicenter, randomized, investigator-blind study ranged in age from 30-65 years and had received previous injections of botulinum toxin type A in the upper face. Over the course of the 120-day trial, 61 patients were randomly assigned (1:1) treatment with either the Condition & Enhance System or a standard skincare regimen.
About the Condition & Enhance System
Condition & Enhance is a 4% hydroquinone-based skin care regimen that, together with the use of tretinoin, creates a system that has been specifically designed to be used daily to optimize facial procedure results. The Condition & Enhance System, which utilizes Obagi Medical's Penetrating Therapeutics™ technology, helps to correct photodamaged skin, promote and maintain the overall health of the skin and prevent future skin damage. The system is available only by prescription.
About Obagi Medical Products, Inc.
Obagi Medical Products' develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics™ technologies, Obagi Medical's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi's skin care product introductions is as follows: Obagi Nu-Derm®, 1988; Obagi-C® Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi® Professional-C (a line of highly stable vitamin C serums), 2005; Obagi® Condition & Enhance™ for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm™ eye treatment and Obagi CLENZIderm® M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm® M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm™ Décolletage System, January 2008, and the Rosaclear™ System for the treatment of rosacea. Visit www.obagi.com for information.
Forward Looking Statements
There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2008. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.
Botox is a registered trademark of Allergan, Inc.
Contact: Press Contact:
Creative Media Marketing
Investor Relations Contact:
Preston Romm, Chief Financial Officer
Posted: July 2009